COMBINED VACCINES IN PEDIATRICIAN PRACTICE
Keywords:
vaccine prophylaxis, combined vaccines, monovaccines, combination of various vaccines, reactivity, effectiveness, safety, children.Abstract
Currently, there is a trend towards reducing the use of invasive methods in pediatrics, which also relates to vaccine prevention. The creation of modern multicomponent vaccines contributes to a reduction in the number of painful injections for infants, since most vaccines are administered in the first year of life.
The article presents convincing data on the high effectiveness and safety of combined vaccines. The possibility of their effective combination with other monovaccines, the absence of a sum of adverse reactions, and even their reduction due to a decrease in the frequency of vaccinations (in the case of using monovaccines) has been shown.
References
1. Cherry J. et al. A search for serologic correlates of immunity to Bordetella pertussiscoughs illnesses. Vaccine. 1998; 16: 1901–1906.
2. Dhillon S. DTPa-HBV-IPV/Hib vaccine (Infanrix hexa). A review of its use as primary and booster vaccination. Drugs. 2010; 70 (8): 1022–1058.
3. Zepp F., Schmitt H-J., Cleerboat J. et al. Rewiev of 8 years of experience with Infanrix hexa (DTPa — HBV-IPV/Hib hexavalent vaccine). Expert rew. Vaccine. 2009; 8 (6): 663–676.
4. Zinke M., Kappes R., Kindler K. et al. Immune memory to hepa- titis B virus in 4–9-year old children vaccinated in infancy with four doses of hexavalent DTPa-HBV-IPV/Hib vaccine. Human Vaccines. 2009; 5 (9): 592–599.
5. Pichichero M. E., Blatter M. M., Reisinger K. S. et al. Impact of a birth dose of hepatitis B vaccine on the reactogenicity and immuno- genicity of diphtheria-tetanus-acellular pertussishepatitis B-inac- tivated poliovirus — Haemophilus influenzae type b combination vaccination. Pediatr Infect Dis J. 2002; 21 (9): 854–859.
6. Fong-Seng L., Htay-Htay H., Jacquet J.-M., Bock H. L. Primary vaccination of infants against hepatitis b can be completed using a combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliomyelitis — Haemophilus influenzae type B vaccine. Annals Academy of Medicine. 2007; 36 (10): 801–806.
7. Omenaca F., Garcia-Sicilia J., Garcia-Corbeira P. et al. Response of preterm newborns to immunization with a hexavalent diphtheria- tetanus-acellular pertussis-hepatitis B virus-inactivated polio and Haemophilus influenzae type b vaccine: first experiences and solutions to a serious and sensitive issue. Pediatrics. 2005; 116 (6): 1292–1298.
8. Kalies H., Grote V., Siedler A. et al. Effectiveness of hexavalent vaccines against invasive Haemophilus influenzae type b disease: Germany’s experience after 5 years of licensure. Vaccine. 2008; 26 (20): 2545–2552.
9. Schmitt H. J., von Koеnig C. H., Neiss A. et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA. 1996; 275 (1): 37–41.
10. Greco D., Salmaso S., Mastrantonio P. et al. On behalf of the Progetto Pertosse Working Group A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med. 1996; 334 (6): 341–348.
11. Информационное Письмо Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека от 18 мая 2007 г. № 0100/5137-07-32 Приложение № 2 «О тактике иммунизации при удлинении интервалов между прививками против гепатита В».
12. Gimenez-Sanchez F., Kieninger D. M., Kueper K. et al. Immuno- genicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccine. Vaccine. 2011; 29: 6042– 6048.
13. Vanden Bergh M. R., Spijkerman J., Francois N. et al. Immuno- genicity, safety, and reactogenicity of the 10-valen tpneumococca lnontypeable Haemophilus influenzae protein D conjugate vaccine and DTPa-IPV-Hib when coadministered as a 3-dose primary vaccinations chedule in the Netherlands. A randomized controlled trial. Pediatr Infect Dis J. 2011; 30: 170–178.
14. Tejedor J., Omenaca F., Garcia-Sicilia J. et al. Immunogenicity and reactogenicity of a three-dose primary vaccination course with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine coadministered with a meningococcal C conjugate vaccine. Pediatr Infect Dis J. 2004; 23 (12): 1109–1115.
15. Knuf M., Pantazi-Chatzikonstantinou A., Pfletschinger U. et al. An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanustoxoidconjugate vaccine co-administered with Infanrix hexa is immunogenic, with an acceptable safety profile in 12–23-month-old children. Vaccine. 2011; 29: 4264–4273.
16. Tejedor J. C., Garcia-Sicilia J., Grunert D. et al. Co-administration of the new 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHID-CV) with other routine paediatric vaccines. 6th International Symposium on Pneumo- cocci & Pneumococcal Diseases (ISPPD-6). Reykjavik, Iceland. 8–12 June 2008.
17. Hviid A., Wohlfahrt J., Stellfeld V., Melbyt M. Childhood vaccination and nontargeted infectious disease hospitalization. JAMA. 2005; 294 (6): 699–705.
